KRAS and hepatocellular carcinoma: There are in vitro and in vivo studies being conducted with darovasertib to determine if it can be used in combination with the KRAS inhibitors, sotorasib and adagrasib, to treat non-small cell lung cancer and hepatocellular carcinoma (Reck et al., 2021).